(HHT) |
| 0 (0%) 01-13 23:53 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.18 |
| Resistance 1: | 1.01 |
| Pivot price: | 0.80 |
| Support 1: | 0.69 |
| Support 2: | 0.50 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Sat, 10 Jan 2026
Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic - Pulse 2.0
Fri, 09 Jan 2026
EcoR1 Capital Joins $125M Series B for Diagonal Therapeutics - citybiz
Thu, 08 Jan 2026
Diagonal moves forward with $125M series B round, plots first-in-human study this year - Fierce Biotech
Thu, 08 Jan 2026
Diagonal Therapeutics secures $125M to start first-in-human genetic disease trial - Endpoints News
Fri, 19 Dec 2025
Atavistik Bio Holds $120 Million Series B Financing to Advance Small Molecule Therapies for HHT and MPNs - Pharmaceutical Executive
Thu, 27 Nov 2025
Vaderis drug lends hope to patients with bleeding disease HHT - pharmaphorum
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
